Acer Therapeutics Inc. (NASDAQ:ACER) Short Interest Update

Acer Therapeutics Inc. (NASDAQ:ACERGet Rating) was the recipient of a large increase in short interest in October. As of October 31st, there was short interest totalling 86,100 shares, an increase of 44.5% from the October 15th total of 59,600 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily trading volume, of 90,700 shares, the days-to-cover ratio is currently 0.9 days.

Acer Therapeutics Price Performance

Shares of NASDAQ ACER opened at $1.23 on Friday. The stock’s fifty day moving average price is $1.34 and its two-hundred day moving average price is $1.58. Acer Therapeutics has a one year low of $1.11 and a one year high of $3.77. The firm has a market cap of $19.61 million, a price-to-earnings ratio of -0.91 and a beta of 1.21.

Acer Therapeutics (NASDAQ:ACERGet Rating) last released its earnings results on Monday, August 15th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.10. On average, equities analysts anticipate that Acer Therapeutics will post -2.63 earnings per share for the current fiscal year.

Institutional Trading of Acer Therapeutics

A number of institutional investors have recently modified their holdings of ACER. Vanguard Group Inc. lifted its position in shares of Acer Therapeutics by 55.5% during the 1st quarter. Vanguard Group Inc. now owns 278,215 shares of the biopharmaceutical company’s stock valued at $807,000 after acquiring an additional 99,335 shares during the period. Copperwynd Financial LLC bought a new stake in shares of Acer Therapeutics during the 2nd quarter worth $29,000. Finally, Renaissance Technologies LLC lifted its position in shares of Acer Therapeutics by 216.8% during the 2nd quarter. Renaissance Technologies LLC now owns 69,700 shares of the biopharmaceutical company’s stock worth $88,000 after buying an additional 47,700 shares during the last quarter. 9.76% of the stock is currently owned by institutional investors.

Acer Therapeutics Company Profile

(Get Rating)

Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.

Further Reading

Receive News & Ratings for Acer Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.